Calcific Uremic Arteriolopathy: A Case Series and Review from an Inner-City Tertiary University Center in End-Stage Renal Disease Patients on Renal Replacement Therapy
Table 3
Types of therapy to manage hyperparathyroidism and the outcome of the CUA lesions.
Patient variables
Frequency (%)
Therapy of hyperparathyroidism
Vitamin D
1 (4.2%)
Cinacalcet
13 (54.2%)
Parathyroidectomy
1 (4.2%)
Alendronate
1 (4.2%)
No treatment
8 (33.3%)
Therapy of calcific uremic arteriolopathy
Received
Did not receive
HBO2
2 (8.3%)
22 (91.7%)
Cinacalcet
13 (54.1%)
11 (45.9%)
Wound care
21 (87.5%)
3 (12.5%)
NaTSO4
22 (91.7%)
2 (8.3%)
PTHx
1 (4.2%)
23 (95.8%)
The outcome of the lesion
Improved
10 (41.7%)
Partially improved
2 (8.3%)
Expired or amputation
12 (50%)
HBO: hyperbaric oxygen therapy, NaTSO4: sodium thiosulphate, PTHx: parathyroidectomy. Patients may be enrolled in multiple types of treatment for calcific uremic arteriolopathy.
